News Express | Physical Function Changes in Pediatric Patients Before and After Hematopoietic Stem Cell Transplantation

News Express | Physical Function Changes in Pediatric Patients Before and After Hematopoietic Stem Cell Transplantation

2024.09.11
The "News Express" column aims to bridge the gap between cutting-edge research and clinical practice, allowing every hematology enthusiast and professional to quickly capture industry trends, spark innovative thinking, and broaden professional horizons. Hematology Frontier carefully selects the latest hematology research findings from top global journals, delivering every brilliant spark of science and clinical practice to you. We invite you to follow this column and join global hematology experts on the journey of scientific exploration!
Dr. Jun Zhu: Advancing Lymphoma Drug Development in China to Propel the Discipline and Hospital Growth

Dr. Jun Zhu: Advancing Lymphoma Drug Development in China to Propel the Discipline and Hospital Growth

2024.09.11
Under the leadership of Dr. Jun Zhu, the Lymphoma Department at Peking Cancer Hospital has become a frontrunner in lymphoma drug development. This year, what innovative achievements from the team will illuminate the treatment path for lymphoma patients? How have they showcased Chinese expertise on the international stage? Additionally, how will the opportunities and challenges China faces in new drug development be transformed into driving forces to enhance lymphoma treatment standards? At the 12th Lu Daopei Hematology Forum, Hematology Frontier had the honor of conducting an in-depth interview with Dr. Jun Zhu. During the discussion, Professor Zhu not only reviewed the illustrious journey of China's lymphoma drug development but also, with his profound insights and forward-looking perspective, envisioned the limitless possibilities in this field's future. Let us delve into Professor Zhu’s remarkable analysis and unique insights on the development of lymphoma drugs in China.
WCLC Expert Commentary: Dr. Nan Bi Discusses the LAURA Study Results and the Challenges of EGFR-Positive LA-NSCLC Targeted Consolidation Therapy

WCLC Expert Commentary: Dr. Nan Bi Discusses the LAURA Study Results and the Challenges of EGFR-Positive LA-NSCLC Targeted Consolidation Therapy

2024.09.11
The 2024 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), is currently underway in San Diego, USA. Oncology Frontier has invited leading Chinese lung cancer experts to analyze the key research data from this conference. This article highlights Dr. Nan Bi from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, as she shares her thoughts on the LAURA study results (Abstract No. OA12.03).
WCLC China Special Session: Exploring Global Lung Cancer Prevention and Evidence-Based Medicine

WCLC China Special Session: Exploring Global Lung Cancer Prevention and Evidence-Based Medicine

2024.09.11
At the 2024 World Conference on Lung Cancer (WCLC), the International Association for the Study of Lung Cancer (IASLC), the Chinese Society of Clinical Oncology (CSCO), and the Chinese Alliance Against Lung Cancer (CAALC) came together once again to host a joint session. Held on Saturday, September 7, from 8:00 AM to 12:00 PM, the session focused on the development and future prospects of evidence-based medicine in lung cancer prevention worldwide. The session was chaired by IASLC President-Elect, Dr. Caizun Zhou from Shanghai East Hospital, alongside Dr. Yilong Wu from Guangdong Provincial People's Hospital, IASLC CEO Dr. Karen Kelly, and Dr. Chunxue Bai from Fudan University’s Zhongshan Hospital.
Dr.Yuankai Shi: INTELLECT Study Reveals mOS of 41.8 Months, Offering Prolonged Survival for NSCLC Patients Resistant to Crizotinib

Dr.Yuankai Shi: INTELLECT Study Reveals mOS of 41.8 Months, Offering Prolonged Survival for NSCLC Patients Resistant to Crizotinib

2024.09.11
The IASLC 2024 World Conference on Lung Cancer (WCLC 2024) was held in San Diego, CA USA on September 7th. The mOS data from the INTELLECT study was disclosed at the conference on September 8th. Oncology Frontier has invited the lead principal investigator of the INTELLECT study, Dr. Yuankai Shi from the Cancer Hospital Chinese Academy of Medical Sciences, to share the latest findings from this groundbreaking research reported at the WCLC. This study highlights the promising outcomes of Iruplinakib treatment for advanced NSCLC patients resistant to crizotinib.
WCLC 2024 | Dr. Patel Discusses the Anticipation for IASLC’s 50th Anniversary Celebration

WCLC 2024 | Dr. Patel Discusses the Anticipation for IASLC’s 50th Anniversary Celebration

2024.09.10
The 2024 World Conference on Lung Cancer (WCLC) marks the 50th anniversary of the International Association for the Study of Lung Cancer (IASLC). This milestone celebration will feature unique activities commemorating IASLC’s rich history, under the theme "Across the Decades." The event will be held on September 8 in San Diego’s famous Gaslamp Quarter, where attendees can enjoy local cuisine, dance, and commemorative attire throughout the evening.
Frontiers in Gynecologic Oncology | Can Severe Endometriosis Significantly Increase the Risk of Ovarian Cancer?

Frontiers in Gynecologic Oncology | Can Severe Endometriosis Significantly Increase the Risk of Ovarian Cancer?

2024.09.09
A large population-based cohort study led by Dr. Mollie E. Barnard from the Huntsman Cancer Institute at the University of Utah has found that women with endometriosis have an overall higher risk of ovarian cancer, with the risk being significantly elevated in those with severe types of endometriosis. This study, published in the journal of the American Medical Association [1], suggests that these women may benefit from counseling on ovarian cancer risk and prevention, as well as potential ovarian cancer screening.
Lung Cancer Guidelines: ASCO Updates Stage III NSCLC Guidelines Based on LAURA Trial Data, Including Osimertinib

Lung Cancer Guidelines: ASCO Updates Stage III NSCLC Guidelines Based on LAURA Trial Data, Including Osimertinib

2024.09.09
The Phase 3 Non-Small Cell Lung Cancer (NSCLC) Treatment ASCO Guidelines has recently been updated, with the revisions based on the results of the Phase 3 LAURA trial. The findings were presented at the 2024 ASCO Annual Meeting and published simultaneously in the New England Journal of Medicine [1, 2]. The new guidelines include a recommendation to use the EGFR-TKI osimertinib in patients with unresectable Stage III NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations after definitive chemoradiotherapy (CRT).